Among KRAS mutations in pancreatic adenocarcinoma, residue G12 mutations (94%) predominate, while G13 and Q61 mutations (1.2 and 2.4%, respectively) are rare [43]. This evidence concerns the gene KRAS and pancreatic adenocarcinoma.